Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regen BioPharma (RGBPP) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Regen BioPharma (RGBPP) over the last 13 years, with Q3 2025 value amounting to -$572469.0.

  • Regen BioPharma's Net Income towards Common Stockholders fell 76866.71% to -$572469.0 in Q3 2025 from the same period last year, while for Dec 2025 it was -$759115.0, marking a year-over-year increase of 752.06%. This contributed to the annual value of -$1.3 million for FY2025, which is 9072.09% down from last year.
  • Regen BioPharma's Net Income towards Common Stockholders amounted to -$572469.0 in Q3 2025, which was down 76866.71% from -$167292.0 recorded in Q2 2025.
  • Regen BioPharma's 5-year Net Income towards Common Stockholders high stood at $60.9 million for Q2 2022, and its period low was -$67.1 million during Q1 2022.
  • Over the past 5 years, Regen BioPharma's median Net Income towards Common Stockholders value was -$117108.0 (recorded in 2024), while the average stood at -$685725.8.
  • Over the last 5 years, Regen BioPharma's Net Income towards Common Stockholders had its largest YoY gain of 91360.66% in 2022, and its largest YoY loss of 1765851.1% in 2022.
  • Over the past 5 years, Regen BioPharma's Net Income towards Common Stockholders (Quarter) stood at $2.4 million in 2021, then crashed by 39.42% to $1.4 million in 2022, then plummeted by 110.0% to -$144913.0 in 2023, then tumbled by 255.65% to -$515384.0 in 2024, then decreased by 11.08% to -$572469.0 in 2025.
  • Its Net Income towards Common Stockholders stands at -$572469.0 for Q3 2025, versus -$167292.0 for Q2 2025 and -$19354.0 for Q1 2025.